Exelixis' Cabometyx (cabozantinib) Recommended by the NCCN in its Clinical Practice Guidelines for advanced RCC despite of patient risk status
Shots:
- Guidelines for Kidney Cancer: CABOMETYX (TKi) is recommended for 1L RCC patients in the poor- and intermediate-risk groups (Category 2A)- 1L treatment for favourable-risk patients (Category 2B)- and for previously treated patients (Category 1)
- The (Category 2A) guidelines are based on P-II CABOSUN trial (N=157) in (ratio 1:1) administering cabozantinib (60mg qw)/sunitinib (50mg qw-4 wks. with 2 wks. off) showing improved PFS results in trial
- Additionally- FDA has accepted cabometyx’s sNDA for previously treated advanced HCC (Child-Pugh Class A only) with PDUFA date of 14 Jan- 2019
/ article | Ref: Exelixis | Image: Glassdoor
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com